The biopharma industry is in an historic period of innovation, with deep pipelines across many difficult-to-treat disease areas, yet numerous challenges may impact whether promising drugs ever get to the patients who need them. In the 2016 Hatfield Lecture on Oct. 27, Biogen CEO George Scangos '70 discussed how innovative biopharma companies are able to bring transformative therapies to patients, work to ensure access to those therapies, and meet the demands of their shareholders.